✦ LIBER ✦

New therapies and new goals for psoriatic arthritis

✍ Scribed by Douglas James Veale

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 39 KB
Volume: 63
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.30173

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sulfasalazine in psoriatic arthritis: A

Sulfasalazine in psoriatic arthritis: A new or established indication?

✍ P. Goupille; J. P. Valat 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 1 views

New hope for mesenchymal cell therapies

📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB 👁 1 views

Sustained benefits of infliximab therapy

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

✍ Christian E. Antoni; Arthur Kavanaugh; Bruce Kirkham; Zuhre Tutuncu; Gerd R. Bur 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Classification criteria for psoriatic ar

Classification criteria for psoriatic arthritis: Development of new criteria from a large international study

✍ William Taylor; Dafna Gladman; Philip Helliwell; Antonio Marchesoni; Philip Meas 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

New approaches to cancer therapies

✍ Fåhraeus, Robin; Fischer, Peter; Krausz, Eberhard; Lane, David P. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 2 views

Inactivation of the tumour suppressors p53 and p16 INK4a or activating mutations in the ras oncogene are the most common genetic alterations found in human cancers. In this review, novel approaches designed to evaluate the effect of targeting intracellular molecules are described and it is shown how

Standing and new policies and procedures

Standing and new policies and procedures for Arthritis & Rheumatism

✍ Michael D. Lockshin 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 2 views